IDUNN MSC0518/Obnitix (#1227)
Laufzeit: 01.01.2021 - 31.12.2040
imported
Kurzfassung
A Randomised, Open-label, Multicentre, Phase 3 Trial of First-line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Haematopoietic Stem Cell Transplantation (IDUNN Trial)